Jeremy Bender - May 1, 2024 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Signature
/s/ Charles N. York II, as Attorney-in-Fact
Stock symbol
DAWN
Transactions as of
May 1, 2024
Transactions value $
-$1,415,707
Form type
4
Date filed
5/3/2024, 06:48 PM
Previous filing
Feb 20, 2024
Next filing
May 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Sale -$1.25M -70.1K -9.7% $17.88 652K May 1, 2024 Direct F1, F2
transaction DAWN Common Stock Sale -$108 -6 0% $17.94 652K May 2, 2024 Direct F1, F3
transaction DAWN Common Stock Sale -$163K -9.15K -1.4% $17.85 643K May 3, 2024 Direct F1, F4
holding DAWN Common Stock 222K May 1, 2024 See footnote F5
holding DAWN Common Stock 300K May 1, 2024 See footnote F6
holding DAWN Common Stock 252K May 1, 2024 See footnote F7
holding DAWN Common Stock 270K May 1, 2024 See footnote F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 3, 2023.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.84 to $18.04 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.85 to $17.955 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.84 to $17.96 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 Represents shares held by The Jeremy Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person is trustee.
F6 Represents shares held by The Jeremy Bender 2023 Grantor Retained Annuity Trust dated June 27, 2023.
F7 Represents shares held by The Melissa Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person's spouse is trustee.
F8 Represents shares held by The Melissa Bender 2023 Grantor Retained Annuity Trust, dated June 27, 2023.